Ascendis Pharma Valuation: Upside After Recent Momentum?

Ascendis Pharma (ASND) has seen a 9% increase in the past 3 months and a 53% YoY gain, driven by commercial and pipeline progress. The stock is valued at $212.33, with a fair value of $257.66, indicating a 17.6% undervaluation. The narrative highlights bold growth assumptions and margin inflection points, but doubts linger about reliance on blockbuster drugs and reimbursement challenges. The company trades at 17.3 times sales, higher than the biotech industry average and fair ratio, potentially heightening the risk of disappointment if growth slows.